Biotech | October 27, 2021
Novavax files for approval of its Covid-19 vaccine in the UK
Filing marks first protein-based vaccine submitted to MHRA for authorization
Filing marks first protein-based vaccine submitted to MHRA for authorization
UFlex has committed close to US $ 10 million towards various initiatives at its overseas and Indian plants to repurpose plastic waste
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
Filing for WHO Emergency Use Authorisation this month
Deal for 100 million doses with additional 100 million through 2023
The first batch will be shipped to the Gamaleya Center for the quality control
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Subscribe To Our Newsletter & Stay Updated
